Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF), a leader in the production of pharmaceutical cannabidiol (CBD) products and in the development of innovative cannabidiol medicines for heart disease, is pleased to announce the formation of the Clinical Steering Committee (CSC) for a Phase 2 international trial in acute myocarditis using the Companys CardiolRx100 cannabidiol formulation.
The CSC, which comprises key opinion leaders in acute myocarditis from North America and Europe, recently met during the American Heart Associations Scientific Sessions in Philadelphia held November 16th to 18th. The role of the CSC is to advise on the trial design, provide overall supervision of the trial, and ensure that it is being conducted in accordance with the principles of Good Clinical Practice. The CSC has oversight of the protocol, any protocol amendments, and provides advice to the investigators on all aspects of the trial.
Acute myocarditis is characterized by inflammation of the heart muscle (myocardium). The most common cause is viral infection of the heart tissue which is initially responsible for the inflammation. In a significant number of cases, perhaps due to an autoimmune process, the inflammation persists with ongoing myocardial damage and depressed heart function. Although the symptoms are often mild, myocarditis remains an important cause of acute and fulminant heart failure and is the most common cause of sudden cardiac death in people less than 35 years old. In addition, some patients proceed to develop chronic dilated cardiomyopathy which continues to be the leading indication for cardiac transplantation. Symptoms include chest pain, fatigue, shortness of breath, and arrhythmias. Because of the progressive damage to heart cells, heart failure develops (defined as the inability of the heart to pump sufficient blood to meet the needs of the body). The study will use left ventricular ejection fraction (LVEF) as one measure of heart function.
CardiolRx100 is Cardiol Therapeutics pure pharmaceutically (cGMP) produced high concentration cannabidiol formulation that is THC free (<10ppm). Based on the large body of experimental evidence of the anti-inflammatory and cardioprotective properties of cannabidiol in models of cardiovascular disease, Cardiol believes there is an opportunity to develop a potential breakthrough therapy for acute myocarditis that would be eligible for designation as an orphan drug. In the United States, an orphan drug designation is granted for pharmaceuticals being developed to treat medical conditions affecting fewer than 200,000 people. These conditions are referred to as orphan diseases. In the U.S. and the European Union, orphan drugs are eligible for accelerated marketing approvals and companies developing orphan drugs typically receive other incentives, including a prolonged period of market exclusivity that can extend over seven years, during which the drug developer has sole rights to market the drug.
Cardiol has assembled eight highly distinguished thought leaders in cardiology from North America and Europe to oversee and guide our acute myocarditis trial that is being planned at world leading heart institutes, including the Cleveland Clinic, the Mayo Clinic, the Houston Methodist DeBakey Heart and Vascular Center, the University of Ottawa Heart Institute, and Charit University Medicine Berlin, stated David Elsley, President and CEO of Cardiol Therapeutics. The U.S. orphan drug program was successfully utilized to accelerate the first FDA approval of cannabidiol for the treatment of two pediatric epilepsy orphan diseases. We see a similar opportunity with our international trial in acute myocarditis to fast track the development of our CardiolRx formulation for a serious cardiovascular orphan disease for which there is currently no accepted standard of care.
Members of Cardiols Acute Myocarditis CSC include:
Dennis M. McNamara, MD (Chair)
Dr. Dennis McNamara is a Professor of Medicine at the University of Pittsburgh. He is also the Director of the Heart Failure/Transplantation Program at the University of Pittsburgh Medical Center. Dr. McNamara received his undergraduate/graduate education at Yale University, New Haven, Connecticut, and Harvard Medical School, Boston, Massachusetts, respectively. He completed his internship, residency, and cardiology fellowship at Massachusetts General Hospital in Boston. McNamaras current research interests include etiology and pathogenesis of dilated cardiomyopathies; inflammatory syndromes of cardiovascular disease; myocardial recovery in recent onset non-ischemic primary cardiomyopathy; etiology and management of peripartum cardiomyopathy; and genetic modulation of outcomes in cardiovascular disease.
Leslie T. Cooper, Jr., MD (Co-Chair)
Dr. Leslie T. Cooper, Jr., is a general cardiologist and the chair of the Mayo Clinic Enterprise Department of Cardiovascular Medicine, as well as chair of the Department of Cardiovascular Medicine at the Mayo Clinic in Florida. Dr. Coopers clinical interests and research focus on clinical and translational studies of rare and undiagnosed cardiomyopathies, myocarditis, and inflammatory cardiac and vascular diseases, such as giant cell myocarditis, cardiac sarcoidosis, eosinophilic myocarditis, and Takayasus arteritis. He has published over 130 original peer-reviewed papers, as well as contributing to and editing books on myocarditis. In addition to his clinical and research work, Dr. Cooper is a fellow of the American College of Cardiology, the American Heart Association, the European Society of Cardiology Heart Failure Association, the International Society for Heart and Lung Transplantation, and the Society for Vascular Medicine and Biology. He is also the founder and former president of the Myocarditis Foundation and continues to serve on its Board of Directors.
Arvind Bhimaraj, MD
Dr. Arvind Bhimaraj is a specialist in Heart Failure and Transplantation Cardiology and is Assistant Professor of Cardiology, Institute for Academic Medicine, at Houston Methodist and at Weill Cornell Medical College, NYC. He has been Co-Director of the Heart Failure Research Laboratory at Houston Methodist since 2016. His area of focus is anti-fibrotic mechanisms and how to promote recovery of a damaged heart. Dr. Bhimaraj was a Heart Failure Fellow at the Cleveland Clinic from July 2010 to September 2011. Dr. Bhimaraj also specializes in Interventional Cardiology, is board certified in Cardiovascular Disease, and the author of numerous cardiovascular publications.
Matthias Friedrich, MD
Dr. Matthias Friedrich is Full Professor with the Departments of Medicine and Diagnostic Radiology at the McGill University in Montreal and Chief, Cardiovascular Imaging at the McGill University Health Centre. He is also Professor of Medicine at Heidelberg University in Germany. Dr. Friedrich earned his MD at the Friedrich-Alexander-University Erlangen-Nrnberg, Germany. He completed his training as an internist and cardiologist at the Charit University Medicine Center, Humboldt University in Berlin. Dr. Friedrich founded one of the first large Cardiovascular Magnetic Resonance centres in Germany at the Charit University Hospital in Berlin. After his move to Canada, from 2004 to 2011, he was Director of the Stephenson Cardiovascular MR Centre at the Libin Cardiovascular Institute of Alberta and Professor of Medicine within the Departments of Cardiac Sciences and Radiology at the University of Calgary, Canada. From 2011 to 2015, he directed the Philippa and Marvin Carsley Cardiovascular MR Centre at the Montreal Heart Institute and was Michel and Renata Hornstein Chair in Cardiac Imaging at the Universit de Montral.
Peter Liu, MD
Dr. Peter Liu is the Chief Scientific Officer and Vice President, Research, of the University of Ottawa Heart Institute, and Professor of Medicine and Physiology at the University of Toronto and University of Ottawa. He was the former Scientific Director of the Institute of Circulatory and Respiratory Health at the Canadian Institutes of Health Research, the major federal funding agency for health research in Canada. Prior to that role, he was the inaugural Director of the Heart & Stroke/Lewar Centre of Excellence in Cardiovascular Research at University of Toronto. Dr. Liu received his MD from the University of Toronto, and postgraduate training at Harvard University. His laboratory investigates the causes and treatments of heart failure, the role of inflammation, and the identification of novel biomarkers and interventions in cardiovascular disease. Dr. Liu has published over 300 peer-reviewed articles in high impact journals and received numerous awards in recognition of his research and scientific accomplishments.
Wai Hong Wilson Tang, MD
Dr. Wai Hong Wilson Tang is the Advanced Heart Failure and Transplant Cardiology specialist at the Cleveland Clinic in Cleveland, Ohio. Dr. Tang is also the Director of the Cleveland Clinics Center for Clinical Genomics; Research Director, and staff cardiologist in the Section of Heart Failure and Cardiac Transplantation Medicine in the Sydell and Arnold Miller Family Heart & Vascular Institute at the Cleveland Clinic. He attended and graduated from Harvard Medical School in 1996, having over 23 years of diverse experience, especially in Advanced Heart Failure and Transplant Cardiology. Dr. Tang is affiliated with many hospitals including the Cleveland Clinic and cooperates with other doctors and physicians in medical groups including The Cleveland Clinic Foundation.
Barry Trachtenberg, MD
Dr. Barry H. Trachtenberg is a cardiologist specializing in heart failure and cardiac transplantation. He is also the director of the Michael DeBakey Cardiology Associates Cardio-Oncology program, an evolving field devoted to prevention and management of cardiovascular complications of cancer therapies such as chemotherapy and radiation. His clinical experience includes heart failure and heart transplantation, mechanical support pumps, and cardio-oncology. He has contributed to multiple publications related to advanced heart failure, cardiac transplantation, regenerative therapies, and ventricular assist devices. Dr. Trachtenberg is a member of the American Heart Association, the International Society for Heart and Lung Transplantation, the Heart Failure Society of America, and the International CardiOncology Society of North America.
Carsten Tschpe, MD
Dr. Carsten Tschpe is Professor of Medicine and Cardiology and Vice Director of the Department of Internal Medicine and Cardiology, Charit University Medicine Berlin. He received his doctorate in medicine in 1993 and has over 140 peer-reviewed publications, including overview and book articles, and 120 international original articles. His research interests include inflammatory cardiomyopathy, diabetic cardiopathy, and ischemic cardiopathy. He also includes diastolic dysfunction, endothelial dysfunction, peptide systems, and experimental and clinical studies in cardiology and stem cells in his research studies. For his outstanding research work, Dr. Tschpe was awarded the prestigious Arthur Weber Prize by the German Cardiac Society Cardiovascular Research.
About Cardiol Therapeutics
Cardiol Therapeutics Inc. (TSX: CRDL)(OTCQX: CRTPF) is focused on producing pharmaceutical cannabidiol (CBD) products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. The Companys lead product, CardiolRx, is designed to be one of the safest and most consistent CBD formulations on the market. CardiolRx is pharmaceutically produced, cGMP certified, and is THC free. The Company plans to commercialize CardiolRx in the billion-dollar market for medicinal cannabinoids in Canada and is also pursuing distribution opportunities in Europe and Latin America.
In heart failure, Cardiol is planning an international clinical study of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The Company is also developing proprietary nanotechnology to uniquely deliver pharmaceutical CBD and other anti-inflammatory drugs directly to sites of inflammation in the heart that are associated with heart failure. Heart failure is the leading cause of death and hospitalization in North America with associated healthcare costs in the U.S. alone exceeding $30 billion. For further information about Cardiol Therapeutics, please visitwww.cardiolrx.com.
- Blood drive to honor Franklin child with cancer - Daily Journal - January 24th, 2020
- UAB scientist studies aging through gray hair, says hair could be rejuvenated - AL.com - January 24th, 2020
- Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - MENAFN.COM - January 24th, 2020
- How will technology shape and disrupt our health care this decade? - Times Union - January 24th, 2020
- Major name scheduled to be in Houston for WWE Royal Rumble PPV - Wrestling News - January 24th, 2020
- LifeCell launches 'Genome-Scope' newborn genetic testing to diagnose over 4000 genetic conditions - Yahoo India News - January 24th, 2020
- Advancells Group, IFC concluded their three-day workshop on Regenerative Medicine - Yahoo India News - January 24th, 2020
- New York-based hair restoration company opens new office in New Jersey - amNY - January 24th, 2020
- Orgel, others push city for help with loss of HealthPlus pool - Auburn Villager - January 24th, 2020
- Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - Business Wire India - January 23rd, 2020
- Biodegradable tube excels at treatment of nerve injuries - New Atlas - January 23rd, 2020
- European Commission Approves Darzalex (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diag -... - January 23rd, 2020
- Breakthrough discovery could lead to one-size-fits-all cancer treatment - The Independent - January 23rd, 2020
- Illumia Therapeutics, Singapore's Latest Full-Service Medispa, Lets You Address Your Beauty And Wellness Needs In One Place - Singapore Tatler - January 23rd, 2020
- Misplaced Assumptions, Where Investments Go Wrong - Seeking Alpha - January 23rd, 2020
- Learning to be relentless - The Daily Republic - January 19th, 2020
- Here's Why Stemline Therapeutics Dropped Today - Motley Fool - January 19th, 2020
- Medics key to spotting signs of child abuse, Abu Dhabi conference hears - The National - January 19th, 2020
- Smart Group & A4M Concluded their First India Conference 2020 - NewsPatrolling - January 19th, 2020
- 'Comfort' or con? Despite money, education, well-off Filipinos turning to questionable treatments - Coconuts - January 13th, 2020
- Doctor's Hospital focused on incorporation of AI and machine learning - EyeWitness News - January 13th, 2020
- Viewpoints: Medicaid Expansion Reveals How Liberal Policies Make For Good Politics; Hey, Congress, What's The Hold Up With Surprise Medical Bills? -... - January 13th, 2020
- White blood cells: Function, ranges, types, and more - Medical News Today - January 10th, 2020
- Tacitus Therapeutics Launches in Collaboration with Mount Sinai to Develop Stem Cell Therapies for Life-Threatening Diseases - PRNewswire - January 10th, 2020
- Tip Sheet: Mesh loaded with T cells shrinks tumors; second dose of CAR-T cells shows potential; and gene-edited cells stay safe as immunotherapy... - January 10th, 2020
- 3D-printed Organs Give Hope to Transplant Patients Now. Powered by - Now. Powered by Northrop Grumman. - January 10th, 2020
- Seattle Childrens faces widening array of lawsuits over fatal mold infections - Seattle Times - January 10th, 2020
- Landisa: My cancer can relapse but here's why I am not afraid of it any longer - News24 - January 10th, 2020
- 'You wouldn't give it to your worst enemy': what it's like to live with Lyme disease - Telegraph.co.uk - January 10th, 2020
- The 'supercells' that cured an infant's grave genetic illness - Japan Today - January 10th, 2020
- Edited Transcript of BYSI.OQ earnings conference call or presentation 18-Dec-19 1:00pm GMT - Yahoo Finance - January 8th, 2020
- How These Practitioners Can Help with New Year, New You Goals - Milwaukee Magazine - January 7th, 2020
- Summerside gym needs donations for three-year-old boy with cancerous brain tumors - The Journal Pioneer - January 7th, 2020
- The woman who spent 7 years in and out of hospital battling rare condition some doctors had never seen - Leicestershire Live - January 7th, 2020
- West Norwood girl, 3, dies in her parents' arms after brave battle with leukaemia - MyLondon - January 7th, 2020
- DuPont, C8 Contamination And The Community Left To Grapple With The Consequences - WVXU - January 7th, 2020
- What are the odds? Stem cell recipient learns her donor is also in Ottawa - Ottawa Citizen - January 3rd, 2020
- Understanding the Key Aspects of a Multiple Myeloma Diagnosis - Curetoday.com - January 3rd, 2020
- The 'supercells' that cured an infant's grave genetic illness - FRANCE 24 - January 3rd, 2020
- How supercells cured an infants grave genetic illness - Raw Story - January 3rd, 2020
- Firm adds a new wrinkle to anti-aging products - Williamson Daily News - January 3rd, 2020
- First Edition: January 3, 2020 - Kaiser Health News - January 3rd, 2020
- Finn the Fabulous to ring treatment bell after leaving hospital - expressandstar.com - January 3rd, 2020
- Conway supports man fighting rare double diagnosis of MS, ALS - THV11.com KTHV - January 1st, 2020
- Predicting shifts in technology and science can be tricky, but here's what could happen in 2020 - inews - January 1st, 2020
- None of these four beaming children would be alive today if a stranger had not given blood - The Sun - January 1st, 2020
- On the Road: A year to remember - WCBI - January 1st, 2020
- 2019: the year gene therapy came of age - Breitbart - January 1st, 2020
- The health stories we won't forget and what 2020 holds - nation.co.ke - January 1st, 2020
- Chinese scientist who claimed he genetically edited babies gets prison term - Los Angeles Times - December 30th, 2019
- Year in Review: Gene Therapy Technology and a Milestone 2019 for Medical Research - News18 - December 30th, 2019
- Finding Joy While Struggling With Infertility Over The Holidays - SheKnows - December 25th, 2019
- The reporter driven to do 'whatever it takes' to conquer cancer and return to the press box - The Athletic - December 25th, 2019
- A blood cancer diagnosis helped me find true happiness - The Guardian - December 25th, 2019
- Michael Schumacher health: Doctor reveals truth about Schumi as Lewis Hamilton is catching up fast to break F1 legend's record - EconoTimes - December 25th, 2019
- Mother and son, together, cope with autism and multiple sclerosis - MLive.com - December 25th, 2019
- Local firm adds a new wrinkle to anti-aging products - Williamson Daily News - December 25th, 2019
- Miracle recovery of rider and her horse after severe injuries - Yorkshire Post - December 25th, 2019
- Before the 90 Days Stephanie is YouTuber Stepanka. Is she really ill & bi? - Starcasm - December 21st, 2019
- Stem Cell Therapy Treatment - Melbourne Stem Cell Centre - December 10th, 2019
- U.S. Stem Cell Training | Regenerative Medicine Training ... - December 10th, 2019
- Injectables Are the Future of K-Beauty Trends in America - Yahoo Lifestyle - December 10th, 2019
- ASH 2019 Roundup: The Latest on CAR T, New Treatments for CLL, and Using Genes to Predict a Common Side Effect - On Cancer - Memorial Sloan Kettering - December 10th, 2019
- Orgenesis and Theracell to Launch Point of Care Cell and Gene Therapy Centers within HYGEIA Group's Hospital Network in Greece - GlobeNewswire - December 10th, 2019
- 2019: The year gene therapy came of age - Jamaica Observer - December 10th, 2019
- Ethan's Army gets a boost - Brockville Recorder and Times - December 10th, 2019
- BREAKING: Baby body parts criminal trial to proceed against Daleiden with possible jail time - Lifesite - December 7th, 2019
- 'I was given a terminal diagnosis and then a new therapy cured my leukaemia' - The Telegraph - December 5th, 2019
- Stem Cell Therapy Market Robust pace of Industry during 2017-2025 - News Description - December 5th, 2019
- A #ReUp of 2019: The year when gene therapy, DNA modifications came of age & saved lives - Economic Times - December 5th, 2019
- 100 greatest innovations of 2019: Best of What's New - Popular Science - December 3rd, 2019
- Susan J. Demas: Right-wing lies on abortion paved the way for Trump - Michigan Advance - December 3rd, 2019
- Alum's New Book Recounts His Fight to Help First Responders Sickened after 9/11 - BU Today - December 3rd, 2019
- Quinn Waters: Weymouth, Massachusetts three-year-old is seeing the world for himself - CBS News - December 2nd, 2019
- 'We didn't worry when 2-year-old refused to use potty - then her lips went blue' - Mirror Online - December 2nd, 2019
- Upstate SC toddler survives rare cancer and the risky procedure used to treat it - Greenville News - December 2nd, 2019
- 13 YEAR OLD BOY WHO SURVIVED RARE CHILDHOOD CANCER TWICE SUPPORTS NEW FUNDRAISING CAMPAIGN - MENAFN.COM - December 2nd, 2019
- Heartbreaking photograph shows the reality of childhood cancer - Yahoo News - December 2nd, 2019
- Family releases photo sharing the reality of childhood cancer - NEWS.com.au - December 2nd, 2019
- "For the first time in 25 years this means hope" - Leeds family fundraising for life-changing MS treatment - Yorkshire Post - December 2nd, 2019